Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584987 | 0.87 | SMN1; SMN2 (0.61) | ALOX15SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL8211068 | 0.83 | ALOX15 (0.55) | ALOX15SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL13502547 | 0.81 | KMT2A (0.54) | ALOX15SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL13502540 | 0.79 | ALOX15 (0.59) | ALOX15SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL8224982 | 0.72 | HPGD (0.74) | ALOX15SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL31703144 | 0.70 | ALOX15 (1.00) | ALOX15SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL13799881 | 0.70 | ALOX15 (1.00) | ALOX15SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL3580872 | 0.69 | ALDH1A1 (0.54) | SMN1; SMN2MAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL3588982 | 0.69 | ALDH1A1 (0.56) | SMN1; SMN2MAPTKMT2AMEN1HPGD | |
| SCHEMBL1788116 | 0.68 | ALDH1A1 (0.57) | ALOX15SMN1; SMN2L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061764-B1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RES & DEV FOUNDATION (IL) | 2014-07-02 | — | — | EP | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| EP-2589597-A2 | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) | Technion Research & Development Foundation (IL) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589597-A2 | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) | Technion Research & Development Foundation (IL) | 2013-05-08 | — | — | EP | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| EP-2061764-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | Technion Research & Development Foundation LTD. (IL) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008023357-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023357-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | NQO1, SIRT5, KEAP1 | ALOX15 1064/4885SMN1; SMN2 991/4885MAPT 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.